Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | BRS3 | P32247 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8375133 | 0.87 | CYP17A1 (0.41) | NAMPTCYP17A1RAB9ABRS3ATR | |
| SCHEMBL18522430 | 0.87 | NAMPT (0.50) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL2107971 | 0.84 | NAMPT (0.48) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL4827917 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL16307603 | 0.83 | CYP17A1 (0.55) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL536056 | 0.83 | NOD2 (0.50) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL15039524 | 0.83 | CYP17A1 (0.55) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL5746021 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9A | |
| SCHEMBL4037373 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL31707397 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951075-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-24 | — | — | US | disclosed |
| US-9951075-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-24 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-9708328-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-18 | — | — | US | disclosed |
| US-9708328-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-18 | — | — | US | disclosed |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciencies Ireland UC (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciencies Ireland UC (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2016-06-09 | — | — | US | disclosed |
| EP-1881834-B1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN R & D IRELAND (IE) | 2012-04-25 | — | — | EP | disclosed |
| US-8022077-B2 | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-09-20 | — | — | US | disclosed |
| US-8022077-B2 | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-09-20 | — | — | US | disclosed |
| EP-1888580-B1 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARM LTD (IE) | 2010-03-03 | — | — | EP | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| US-20090131460-A1 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131460-A1 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-05-21 | — | — | US | disclosed |
| WO-2006120251-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-11-16 | — | — | WO | disclosed |
| WO-2004024159-A1 | INHIBITORS OF TFGβ | SCIOS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131460-A1 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | DPYD, TYMP, PNP | NAMPT 52/4885CYP17A1 4222/4885RAB9A 2878/4885 |
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | HCCS, HAVCR2, MAVS | NAMPT 12/4885CYP17A1 2834/4885RAB9A 1584/4885 |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | HCCS, HAVCR2, MAVS | NAMPT 12/4885CYP17A1 2834/4885RAB9A 1584/4885 |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | HCCS, HAVCR2, MAVS | NAMPT 12/4885CYP17A1 2834/4885RAB9A 1584/4885 |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | HCCS, HAVCR2, MAVS | NAMPT 12/4885CYP17A1 2834/4885RAB9A 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.